<DOC>
	<DOCNO>NCT01476345</DOCNO>
	<brief_summary>The purpose study determine pharmacokinetics pharmacodynamics LY2963016 compare basal insulin . The study also gather information safety tolerability LY2963016 healthy participant . Each study period approximately 8.5 day ( 1.5 day treatment 7 day washout period ) . There 4 study period .</brief_summary>
	<brief_title>A Study Compare Pharmacokinetics Pharmacodynamics LY2963016 Lantus Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>overtly healthy male female , determine medical history physical examination male participant : agree use reliable method birth control study . female participant childbearing potential must test negative pregnancy time enrollment agree either abstain sexual activity use medically accept mean contraception engage sexual intercourse throughout study , female participant childbearing potential due surgical sterilization menopause body weight least 55 kilogram ( kg ) , body mass index ( BMI ) 18.5 32.0 kilograms/square meter ( kg/mÂ² ) clinical laboratory test result within normal reference range population venous access sufficient allow blood sample reliable willing make available duration study willing follow study procedure give write informed consent participant normal oral glucose tolerance test currently enrol , complete discontinue within last 30 day , clinical trial involve investigational product investigational product use study ; concurrently enrol type medical research judge scientifically medically compatible study know allergy heparin , insulin glargine , related compound component formulation person previously receive investigational product study , complete withdrawn study study investigate LY2963016 abnormality 12lead electrocardiogram ( ECG ) , opinion investigator , increase risk associate participate study abnormal blood pressure determine investigator significant history presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , haematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication show evidence significant active neuropsychiatric disease regularly use know drug abuse and/or show positive finding urinary drug screen show evidence human immunodeficiency virus ( HIV ) infection and/or positive human HIV antibody show evidence hepatitis C and/or positive hepatitis C antibody show evidence hepatitis B and/or positive hepatitis B surface antigen woman positive pregnancy test woman lactate intend use overthecounter prescription medication donate blood 500 milliliter ( mL ) within last 56 day dose Period 1 average weekly alcohol intake exceed 21 unit per week ( male ) 14 unit per week ( female ) , unwilling stop alcohol consumption 24 hour dose throughout duration study period smoke 10 cigarette ( equivalent tobacco product ) per day fast blood glucose &gt; 5.5 millimoles/Liter ( mmol/L ) [ &gt; 99 milligrams/deciliter ( mg/dL ) ] screen positive test antiLY2963016 antiglargine antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>